1.5 Million Euro Extra for Infection Control Scale-up LipoCoat
Series A Funding & Lab Opening
Jasper van Weerd
April 15, 2020
Introduction
LipoCoat receives €1.5 million additional funding to accelerate market entry for infection control innovations. €1.5 Million Infection Control InvestmentFunding provided by Dutch informal investors, High Tech Fund Enschede, and Innovation Fund Rabobank allows LipoCoat to open its dedicated lab at Kennispark Twente and accelerate contact lens and catheter market entry.
€1.5 Million Infection Control InvestmentFunding provided by Dutch informal investors, High Tech Fund Enschede, and Innovation Fund Rabobank allows LipoCoat to open its dedicated lab at Kennispark Twente and accelerate contact lens and catheter market entry.
Jasper van Weerd
CEO / Founder
Jasper van Weerd is CEO of Lipocoat and founder of the LipoCoat coating technology, translating lipid-based science into products that improve the safety, comfort and performance of medical devices.
Updates
Also interesting
LipoCoat and SonoCoat have earned recognition from leading institutions and regulatory bodies. Our coatings meet the highest standards for biocompatibility and clinical efficacy.
News
LipoCoat celebrates its 10th anniversary and breaks ground on a new production lab in Enschede.
LipoCoat is building a 500-square-meter production lab across from the University of Twente and is marking its tenth anniversary. Constantijn van Oranje started construction.
Publication
SonoCoat® Technology Featured in Scientific Publications
Four independent peer-reviewed studies have evaluated SonoCoat®, from EUS-FNA needles to prostate brachytherapy. What each one tested, and what it found.
Document
When the Needle Disappears: SonoCoat® in Three Clinical Applications
Real-time ultrasound guidance is now standard for CVC placement, yet needles still vanish at steep insertion angles. What SonoCoat® changes in vascular access, biopsy and regional anesthesia.